Responses
Regular and Young Investigator Award Abstracts
Other
1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC
Compose a Response to This Article
Other responses
No responses have been published for this article.